After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Part of story

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Artiva Biotherapeutics halted development of its experimental cell therapy for autoimmune conditions following two patient deaths in clinical trials and announced massive workforce reductions.

Oct 27, 20264 sourcesCorporate restructuring Corporate layoffs FDA regulation Clinical trials Biotech innovation Autoimmune disease treatments Drug safety

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Other sources for this story

Endpoints

Artiva to wind down after two patient deaths in autoimmune cell therapy trials

Reuters

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94% | Reuters

BioPharma Dive

After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Part of story

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Other sources for this story

Artiva to wind down after two patient deaths in autoimmune cell therapy trials

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94% | Reuters

Artiva to quit autoimmune cell therapy work, cut staff after patient deaths

After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Part of story

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Other sources for this story

Artiva to wind down after two patient deaths in autoimmune cell therapy trials

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94% | Reuters

Artiva to quit autoimmune cell therapy work, cut staff after patient deaths